#Poland #Biosimilars #Chime Biologics #Polpharma Biologics #Gdańsk

Chime Biologics, a prominent global Contract Development and Manufacturing Organization (CDMO), has made headlines with its recent partnership with Polpharma Biologics, a leading player in the biosimilars sector. This strategic alliance aims to significantly accelerate the development and launch of biosimilar products across the globe, with a particular focus on markets in Europe and beyond.

The partnership seeks not only to enhance the biosimilar development process from the investigational new drug (IND) phase to commercial production but also to establish a robust framework for global market access. Under the terms of this agreement, Chime Biologics will play a crucial role in providing comprehensive support to Polpharma Biologics, ensuring that the transition from development to market supply is as efficient and effective as possible.

Meeting the Growing Demand for Biosimilars

As the global demand for biosimilars continues to rise, this collaboration could not come at a better time. Polpharma Biologics, recognized as the largest biotechnology company in Poland, boasts an impressive portfolio that includes both early and late-stage biosimilar products. With two drugs already approved by regulatory authorities such as the FDA and EMA, Polpharma is well-positioned to leverage its extensive experience while benefitting immensely from Chime Biologics' end-to-end service offerings.

Chime Biologics has established itself as a leader in the biosimilars space, providing state-of-the-art facilities and a diverse range of services that include cell line development, process optimization, and regulatory support. This partnership will enable them to fast-track the development cycle and bring innovative products to market swiftly, ultimately meeting patient needs more rapidly than ever before.

Statements from Leaders

Dr. Jimmy Wei, President of Chime Biologics, expressed enthusiasm about the collaboration, stating, "We are thrilled to contribute to Polpharma Biologics' growth by providing all-in-one solutions that accelerate biosimilar development and reduce time-to-market issues. This partnership reinforces our commitment to delivering high-quality biologics that are affordable for patients around the world."

Konstantin Matentzoglu, a Member of the Supervisory Board of Polpharma Biologics Group VL, pointed out the strategic importance of the partnership, saying, "Working with Chime Biologics aligns with our vision to expedite the introduction of affordable biosimilars in Europe into the global market. Together, we aim to enhance patient access to these vital therapies, solidifying our position as a leading developer in the biosimilars field while optimizing costs through collaboration with Asian partners."

About Chime Biologics and Polpharma Biologics

Chime Biologics specializes in the development and manufacturing of biologics, offering services ranging from pre-clinical support to commercial-scale production. Their mission is to make cutting-edge biomedicines accessible and affordable globally. For more information about Chime Biologics, visit their website at www.chimebiologics.com.

Polpharma Biologics, on the other hand, stands out with its integrated operations throughout the European Union, dedicated to developing biosimilar medicines for various therapeutic areas. The company’s comprehensive approach, from cell line development to clinical trials, positions it well for successful collaborations aimed at meeting the world’s healthcare needs. For further details, check out their site at www.polpharmabiologics.com/en/.